Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials

Author: Vandana Singh | September 05, 2024 09:47am

Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

QWINT-1 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin glargine for 52 weeks in insulin naïve patients.

• The trial met its primary endpoint of non-inferior A1C (blood sugar) reduction with efsitora compared to insulin glargine at week 52.
• For the efficacy estimand, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine, resulting in an A1C of 6.92% and 6.96%, respectively.
• For the treatment-regimen estimand, efsitora reduced A1C by 1.19% compared to 1.16% for insulin glargine, resulting in an A1C of 7.05% and 7.08%, respectively.

Also Read: FDA Rejects Novo Nordisk’s Weekly Insulin, Requests Information Related To Manufacturing Process, Type 1 Diabetes.

QWINT-3 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 78 weeks in adults with type 2 diabetes currently treated with basal insulin.

• The QWINT-3 trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 26. For the efficacy estimand, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec resulting in an A1C of 6.93% and 7.03%, respectively8.
• For the treatment-regimen estimand, efsitora reduced A1C by 0.81% compared to 0.72% for insulin degludec resulting in an A1C of 6.99% and 7.08%, respectively.

Additionally, participants taking efsitora or insulin degludec spent approximately two hours more time in range (glucose 70-180 mg/dL) per day for weeks 22-26 compared to baseline.

• For the efficacy estimand, participants taking efsitora spent 62.8% of time in range compared to 61.3% for insulin degludec for weeks 22-2612.
• For the treatment-regimen estimand, participants taking efsitora spent 61.4% of time in range compared to 61% for insulin degludec14.
• Further, for the efficacy estimand, participants taking efsitora spent 38.3% of time in tight range (glucose 70-140 mg/dL) compared to 36.8% for insulin degludec for weeks 22-2615.

Price Action: LLY stock is down 2.25% at $925.03 at the last check on Thursday.

Read Next:

• Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates.

Photo via Shutterstock

Posted In: LLY